Introduction {#s1}
============

Cancer is recognized as one of the leading causes of death in economically developed countries as well as in developing countries. With the estimated 12.7 millions of cancer cases and 7.6 millions of cancer deaths occurred in 2008, cancer has become a major public health challenge \[[@B1]\]. Because of the combination of earlier detection and improved treatment, the overall cancer mortality is decreasing over the last decade. However, the global burden of cancer continues to increase, largely due to the increased longevity and subsequent growth of the world populations that increasingly adopt cancer-causing behaviors \[[@B1]\]. While the mechanism of carcinogenesis is still not fully understood, it has been suggested that environmental factors, interplaying with low-penetrance susceptibility genes, may be important in the development of cancer \[[@B2],[@B3]\].

Leptin (LEP, also called OB for obese), an adipocyte-derived hormone, produced predominantly by white adipose tissue, regulates appetite and weight, body metabolism and reproductive functions together with the leptin receptor (LEPR) ([Figure **1**](#pone-0075135-g001){ref-type="fig"}) \[[@B4]\]. The *LEP* gene, located at chromosome 7q31.3, encodes a 16 kDa protein that has been consistently shown to be associated with endocrinologic metabolism \[[@B5]\]. It has been also suggested that leptin could contribute to serum insulin levels and the development of type 2 diabetes \[[@B6]\] and that leptin is involved in the pathophysiology of obesity \[[@B7],[@B8]\] and carcinogenesis \[[@B9]-[@B14]\]. Leptin exerts its physiological action through its receptor (LEPR, also called CD295, and its gene is located at chromosome 1p31), which is a single transmembrane protein distributed in many types of tissues \[[@B15]\].

![Gene structural characteristics of leptin and leptin receptor and their roles in regulating adipose tissue mass.\
The locations of *LEP* G2548A (A) and *LEPR* Q223R (B) with possible leptin functions and the pathway of regulating adipose tissue mass (C).](pone.0075135.g001){#pone-0075135-g001}

*LEP* and *LEPR* are highly polymorphic, and a number of single nucleotide polymorphisms (SNPs) have been identified in these two genes \[[@B6],[@B8],[@B16],[@B17]\]. For example, there are at least 383 reported SNPs in the *LEP* gene region and 3117 reported SNPs in the *LEPR* gene region (<http://www.ncbi.nlm.nih.gov/projects/SNP>). However, only few of these reported SNPs are potentially functional and ever studied for their associations with cancer susceptibility. For *LEP*, there are two SNPs that reportedly change amino acid of the protein but only G2548A (rs7799039) was extensively investigated for its association with cancer risk; for *LEPR*, there are five common (minor allele frequency \> 0.05) SNPs that may cause amino acid changes, but only Q223R (rs1137101) was studied for its association with cancer susceptibility. Because the results from these studies are inconsistent \[[@B9]-[@B14],[@B16],[@B18]-[@B40]\], we performed a meta-analysis of the published reports to further evaluate the association of these two SNPs with the risk of cancer.

Materials and Methods {#s2}
=====================

Identification and eligibility of relevant studies {#s2.1}
--------------------------------------------------

Published studies were included, if they met the following three inclusion criteria: (a) evaluating the association between *LEP* G2548A (or A19G) and/or *LEPR* Q223R SNPs and cancer risk, (b) using a case-control design, (c) providing sufficient data for calculation of an odds ratio (OR) with 95% confidence interval (CI).

We searched electronic literature MEDLINE, EMBASE, Web of Science and Chinese Biomedical (CBM) ([[http://www.imicams.ac.cn]{.ul}](http://www.imicams.ac.cn/)) databases for all relevant articles using the search terms: "leptin or LEP", "leptin receptor gene or LEPR", "variant, variation or polymorphism" and "cancer, carcinoma or tumor" (the last search was updated on March 10, 2013). All eligible studies were retrieved, and their bibliographies were manually checked for other relevant publications. Review articles and bibliographies of other relevant studies identified were hand-searched as well to find additional eligible studies. Only published studies with full-text articles in English or Chinese were included. If more than one article was published using the same patient population, only the latest or the largest study was used in this meta-analysis. Two authors independently assessed the articles for compliance with the inclusion criteria, and disagreement was resolved by discussions until the consensus was reached.

Data extraction {#s2.2}
---------------

The following information was collected from each study: first author\'s surname, publication date, ethnicity of the study population, cancer type, source used for controls, total number of cases and controls, and numbers of cases and controls with the AA, AG and GG genotypes for *LEP* G2548A and *LEPR* Q223R, respectively.

Genotype and gene expression correlation analysis {#s2.3}
-------------------------------------------------

The data on *LEP* and *LEPR* genotype and transcript (mRNA) expression levels were available online (http://app3.titan.uio.no/biotools/help.php?app=snpexp) \[[@B41]\]. The genotyping data were derived from The HapMap phase II release 23 data set consisting of 3.96 million SNP genotypes from 270 individuals from four populations (CEU: 90 Utah residents with ancestry from northern and western Europe; CHB: 45 unrelated Han Chinese in Beijing; JPT: 45 unrelated Japanese in Tokyo; YRI: 90 Yoruba in Ibadan, Nigeria) \[[@B42],[@B43]\]. The transcript (mRNA) expression data by genotypes were from EBV-transformed B lymphoblastoid cell lines from the same 270 individuals \[[@B44],[@B45]\].

Statistical methods {#s2.4}
-------------------

The strength of associations of *LEP* G2548A and *LEPR* Q223R SNPs with cancer risk was assessed by calculating ORs with the corresponding 95% CIs. For *LEP* G2548A, the pooled ORs were performed for homozygous model (AA vs. GG), heterozygous model (AG vs. GG), recessive model (AA vs. AG+GG), and dominant model (AA+AG vs. GG). For *LEPR* Q223R, the pooled ORs were also performed for homozygous model (GG vs. AA), heterozygous model (AG vs. AA), recessive model (GG vs. AG+AA), and dominant model (GG+AG vs. AA). The homogeneity assumption was verified by using a Chi square-based Q-test. If the studies were found to be homogeneous (with *P*\>0.10 for the Q test), the pooled OR estimate of all studies was calculated by the fixed-effects model (the Mantel--Haenszel method) \[[@B46]\]. If homogeneity could not be assumed, a random-effects model (the DerSimonian and Laird method) was used \[[@B47]\]. Subgroup analyses were performed by cancer type, ethnicity, study design and sample size (i.e., no. of cases ≥150 vs. no. of cases \<150). To verify the presence of potential publication bias, a standard error of log (OR) for each study was plotted against its log (OR). Funnel plot asymmetry was assessed by Egger's linear regression test \[[@B48]\]. To assess the effect of individual studies on the overall risk of cancers, sensitivity analyses were performed by excluding each study individually and recalculating the ORs and 95% CI. The mRNA expression levels between the strata were assessed by using a Student's *t* test, and the trend tests of transcript expression levels by genotypes were evaluated by using General linear model. This meta-analysis was performed using the software STATA version 10.0 (Stata Corporation, College Station, TX) and SAS software (version 9.1; SAS Institute, Cary, NC). All *P* values were two-sided, and a *P*\<0.05 was considered statistically significant.

Results {#s3}
=======

Study characteristics {#s3.1}
---------------------

As shown in [Figure **2**](#pone-0075135-g002){ref-type="fig"}, a total of 115 published records were retrieved, of which 85 were excluded after the abstracts were found to be irrelevant, and three papers were excluded, for two \[[@B49],[@B50]\] of which were covered by another study \[[@B11]\], and one was written in Russian \[[@B26]\]. Finally, 27 papers met the inclusion criteria and were included in the meta-analysis ([Table **1**](#pone-0075135-t001){ref-type="table"}). Overall, 16 studies with 6569 cases and 8405 controls investigated the *LEP* G2548A (or A19G) SNP, and another 19 studies with 7504 cases and 9581 controls investigated the *LEPR* Q223R SNP. The study of Teras et al. \[[@B29]\] on the two SNP was included only in the calculation of the dominant model, because the genotype distribution was not presented in enough detail.

![Flow chart of included studies for this meta-analysis.](pone.0075135.g002){#pone-0075135-g002}

10.1371/journal.pone.0075135.t001

###### Characteristics of studies included in the meta-analysis.

  Surname         Year   Country            Ethnicity        Cancer type          cases/controls   Source of controls   Genotype method   Polymorphisms
  --------------- ------ ------------------ ---------------- -------------------- ---------------- -------------------- ----------------- ---------------
  Kote-Jarai      2003   UK                 Caucasian        Prostate cancer      273/262          PB\*                 PCR-RFLP          Q223R
  Ribeiro         2004   Portugal           Caucasian        Prostate cancer      143/118          HB                   PCR-RFLP          G2548A
  Ribeiro         2006   Portugal           Caucasian        Lung cancer          102/342          HB                   PCR-RFLP          G2548A
  Woo             2006   Korea              Asian            Breast cancer        45/45            HB                   PCR-sequencing    Q223R
  Snoussi         2006   Tunisia            African          Breast cancer        308/222          HB                   PCR-RFLP          G2548A, Q223R
  Gallicchio      2007   USA                Caucasian        Breast cancer        53/872           PB                   TaqMan            Q223R
  Han             2008   China              Asian            Breast cancer        240/500          HB                   PCR-RFLP          Q223R
  Okobia          2008   Nigeria            African          Breast cancer        209/209          HB                   PCR-RFLP          Q223R
  Ulybina         2008   Russia             Caucasian        Breast cancer        110/105          HB                   Real-time PCR     Q223R
  Slattery        2008   USA                Mixed            Colorectal cancer    1565/1965        Mixed                TaqMan            G2548A
  Doecke          2008   Australia          Caucasian        Esophageal cancer    261/1352         PB                   Sequenom iPLEX    G2548A, Q223R
  Ulybina         2008   Russia             Caucasian        Endometrial cancer   191/105          HB                   Real-time PCR     Q223R
  Teras           2009   USA                Caucasian        Breast cancer        641/650          PB                   SNPstream         G2548A, Q223R
  Moore           2009   Finland            Caucasian        Prostate cancer      947/863          PB                   TaqMan            G2548A
  Wang            2009   USA                Caucasian        Prostate cancer      253/257          PB                   TaqMan            G2548A
  Yapijakis       2009   Greece & Germany   Caucasian        Oral cancer          150/152          HB                   PCR-RFLP          G2548A, Q223R
  Pechlivanis     2009   Czech              Caucasian        Colorectal cancer    659/711          HB                   TaqMan            G2548A, Q223R
  Vašků           2009   Czech              Caucasian        Colorectal cancer    100/100          HB                   PCR-sequencing    G2548A, Q223R
  Tsilidis        2009   USA                Mixed            Colorectal cancer    204/362          PB                   TaqMan            G2548A
  Chovanec        2009   Czech              Caucasian        Endometrial cancer   66/66            HB                   Unknown           G2548A
  Cleveland       2010   USA                Caucasian        Breast cancer        1059/1101        PB                   Unknown           G2548A, Q223R
  Partida-Perez   2010   Mexico             Latin American   Colorectal cancer    68/102           HB                   PCR-RFLP          G2548A
  Dai             2010   China              Asian            Hepatocellular       82/102           HB                   PCR-RFLP          Q223R
  Nyante          2011   USA                Mixed            Breast cancer        1972/1775        PB                   Illumina          Q223R
  Kim             2012   Korea              Asian            Breast cancer        390/447          HB                   MassARRAY         Q223R
  Li              2012   China              Asian            Lung cancer          744/832          PB                   PCR-RFLP          Q223R
  Kim             2012   Korea              Asian            Gastric cancer       48/48            HB                   PCR-RFLP          G2548A, Q223R

Notes: LEP G2548A is in high linkage disequilibrium with A19G; \* Spouses of patients with CRC.

HB, Hospital based; PB, Population based; RFLP, Restriction fragment length polymorphisms polymerase chain reaction.

Meta-analysis results {#s3.2}
---------------------

The overall results suggested a statistically significant association between *LEP* G2548A (or A19G) and risk of cancer (AA vs. GG: OR=1.27, 95% CI=1.05-1.54; AA vs. AG+GG: OR=1.19, 95% CI=1.00-1.41) ([Table **2**](#pone-0075135-t002){ref-type="table"}, [Figure **3**](#pone-0075135-g003){ref-type="fig"}). In the subgroup analysis by ethnicity, a statistically significant association was found for Caucasians (AA vs. GG: OR=1.24, 95% CI=1.01-1.53; recessive model: OR=1.23, 95% CI=1.01-1.51) and Africans (AA vs. GG: OR=3.17, 95% CI=1.54-6.51; recessive model: OR=2.62, 95% CI=1.31-5.26) but not for other ethnic groups. In the subgroup analysis by tumor type, the *LEP* 2548A (or 19G) allele was significantly associated with risk of prostate cancer (AA vs. AG+GG: OR=1.26, 95%CI=1.05-1.51) but not with cancers of the breasts and colorectal or other specified cancers. In the subgroup analysis by sample size, a statistically significant association was found for studies with sample sizes \<150 (AA vs. GG: OR=1.78, 95% CI=1.24-2.54; AA vs. AG+GG: OR=1.33, 95% CI=1.00-1.78) but not for those with sample sizes ≥150.

10.1371/journal.pone.0075135.t002

###### Meta-analysis of the association between *LEP* G2548A polymorphism and cancer risk.

  Variables              No. of studies^a^   Homozygous co-dominant   *P* ~het~ ^b^   Heterozygous co-dominant   *P* ~het~ ^b^   Recessive          *P* ~het~ ^b^   Dominant            *P* ~het~ ^b^
  ---------------------- ------------------- ------------------------ --------------- -------------------------- --------------- ------------------ --------------- ------------------- ---------------
                                             AA vs. GG                                AG vs. GG                                  (AA vs. AG+GG)                     (AA+AG vs. GG)      
  All                    15                  1.27 (1.05-1.54)         0.003           1.04 (0.96-1.13)           0.154           1.19 (1.00-1.41)   0.000           1.08 (0.97-1.20)    0.089
  Cancer type                                                                                                                                                                           
  Breast                 2                   1.91 (0.82-4.45)         0.025           1.02 (0.86-1.21)           0.033           1.74 (0.96-3.17)   0.088           1.12 (0.85-1.46)    0.030
  Colorectal             5                   0.97 (0.78-1.20)         0.216           1.03 (0.92-1.17)           0.188           0.92 (0.81-1.05)   0.532           1.02 (0.84-1.23)    0.160
  Prostate               3                   1.42 (0.94-2.12)         0.138           1.13 (0.94-1.36)           0.068           1.26 (1.05-1.51)   0.501           1.30 (0.92-1.84)    0.060
  Others                 5                   1.32 (0.91-1.92)         0.270           0.96 (0.74-1.24)           0.736           1.27 (0.79-2.08)   0.004           1.02 (0.80-1.32)    0.952
  Ethnicity                                                                                                                                                                             
  Caucasian              10                  1.24 (1.01-1.53)         0.036           0.99 (0.89-1.10)           0.333           1.23 (1.01-1.51)   0.003           1.03 (0.93-1.15)    0.299
  Latin American         1                   2.53 (0.89-7.18)         /               2.97 (1.17-7.50)           /               1.08 (0.53-2.21)   /               2.83 (1.15-6.98)    /
  African                1                   3.17 (1.54-6.51)         /               1.45 (1.01-2.07)           /               2.62 (1.31-5.26)   /               1.62 (1.14-2.29)    /
  Asian                  1                   0.88 (0.05-14.69)                        1.29 (0.07-22.42)                          0.69 (0.30-1.61)                   1.00 (0.06-16.46)   /
  Mixed                  2                   0.94 (0.79-1.13)         0.455           1.05 (0.91-1.22)           0.796           0.96 (0.76-1.19)   0.213           1.02 (0.89-1.17)    0.899
  Source of controls                                                                                                                                                                    
  Hospital               9                   1.70 (1.10-2.61)         0.002           1.10 (0.94-1.29)           0.028           1.39 (0.99-1.95)   0.003           1.28 (0.97-1.69)    0.011
  Population             5                   1.22 (1.05-1.41)         0.604           0.99 (0.88-1.13)           0.894           1.15 (0.95-1.38)   0.074           1.03 (0.93-1.15)    0.923
  Mixed                  1                   0.92 (0.76-1.11)         /               1.06 (0.91-1.23)           /               0.89 (0.75-1.05)   /               1.02 (0.88-1.17)    /
  Sample size in cases                                                                                                                                                                  
  \< 150                 6                   1.78 (1.24-2.54)         0.677           1.29 (0.98-1.71)           0.060           1.33 (1.00-1.78)   0.397           1.44 (0.98-2.13)    0.120
  \>=150                 9                   1.16 (0.95-1.43)         0.003           1.02 (0.94-1.11)           0.588           1.16 (0.95-1.41)   0.000           1.03 (0.95-1.12)    0.360

^a^ Only presented the study with enough detail, one study was included only in the calculation of the dominant model.

^b^ *P* value of the Q-test for heterogeneity test.

![Forest plot for AA vs. GG of *LEP* G2548A polymorphism.](pone.0075135.g003){#pone-0075135-g003}

For the *LEPR* Q223R SNP, no statistically significant association with cancer risk was found ([Table **3**](#pone-0075135-t003){ref-type="table"}, [Figure **4**](#pone-0075135-g004){ref-type="fig"}). In the stratified analysis by ethnicity, however, a statistically significant association was observed for Africans (GG vs. AA: OR=1.85, 95% CI=1.23-2.79; GA vs. AA: OR=1.48, 95% CI=1.08-2.01; GG vs. GA+AA: OR=1.48, 95% CI=1.07-2.05; GG+GA vs. AA: OR=1.58, 95% CI=1.14-2.20), but not for Caucasians and other ethnic populations. No statistically significant association was found in the further stratification by tumor type, source of controls, and sample size.

10.1371/journal.pone.0075135.t003

###### Meta-analysis of the association between *LEPR* Q223R polymorphism and cancer risk.

  Variables              No. of studies^a^   Homozygous co-dominant   *P* ~het~ ^b^   Heterozygous co-dominant   *P* ~het~ ^b^   Recessive          *P* ~het~ ^b^   Dominant           *P* ~het~ ^b^
  ---------------------- ------------------- ------------------------ --------------- -------------------------- --------------- ------------------ --------------- ------------------ ---------------
                                             GG vs. AA                                AG vs. AA                                  (GG vs. AG+AA)                     (GG+AG vs. AA)     
  All                    18                  1.02 (0.76-1.39)         0.000           1.08 (0.88-1.34)           0.000           0.98 (0.82-1.18)   0.000           1.03 (0.83-1.29)   0.000
  Cancer type                                                                                                                                                                          
  Breast                 9                   0.94 (0.62-1.42)         0.000           0.97 (0.72-1.31)           0.000           0.95 (0.76-1.20)   0.000           0.93 (0.70-1.24)   0.000
  Colorectal             2                   1.15 (0.86-1.53)         0.507           1.25 (0.70-2.23)           0.090           1.09 (0.85-1.39)   0.789           1.23 (0.76-1.98)   0.130
  Prostate               1                   0.82 (0.52-1.29)         /               0.85 (0.58-1.26)           /               0.89 (0.59-1.34)   /               0.84 (0.59-1.19)   /
  Others                 6                   1.09 (0.49-2.39)         0.000           1.27 (0.83-1.94)           0.029           1.04 (0.62-1.75)   0.000           1.17 (0.90-1.96)   0.000
  Ethnicity                                                                                                                                                                            
  Caucasian              9                   1.08 (0.84-1.40)         0.020           1.10 (0.96-1.26)           0.363           0.98 (0.78-1.24)   0.006           1.06 (0.91-1.23)   0.075
  East Asian             6                   0.44 (0.08-2.48)         0.000           0.49 (0.11-2.13)           0.000           0.79 (0.46-1.36)   0.000           0.44 (0.09-2.33)   0.000
  African                2                   1.85 (1.23-2.79)         0.275           1.48 (1.08-2.01)           0.302           1.48 (1.07-2.05)   0.403           1.58 (1.14-2.20)   0.245
  Mixed                  1                   0.91 (0.76-1.09)         /               0.92 (0.78-1.08)           /               0.97 (0.84-1.12)   /               0.92 (0.79-1.06)   /
  Source of controls                                                                                                                                                                   
  Hospital               12                  0.86 (0.49-1.51)         0.000           0.99 (0.69-1.43)           0.000           0.89 (0.66-1.19)   0.000           0.90 (0.60-1.38)   0.000
  Population             6                   1.22 (0.84-1.76)         0.000           1.14 (0.86-1.51)           0.000           1.12 (0.90-1.39)   0.001           1.11 (0.84-1.46)   0.000
  Sample size in cases                                                                                                                                                                 
  \< 150                 6                   0.89 (0.37-2.12)         0.014           1.08 (0.55-2.13)           0.046           0.84 (0.51-1.38)   0.040           1.03 (0.53-2.01)   0.034
  \>=150                 12                  1.04 (0.75-1.46)         0.000           1.07 (0.85-1.35)           0.000           1.02 (0.84-1.24)   0.000           1.02 (0.80-1.31)   0.000

^a^ Only presented the study with enough detail, one study was included only in the calculation of the dominant model.

^b^ *P* value of the Q-test for heterogeneity test.

![Forest plot for the *LEPR* Q223R polymorphism (recessive model).](pone.0075135.g004){#pone-0075135-g004}

The mRNA expression by genotypes {#s3.3}
--------------------------------

The mRNA expression levels of *LEP* and *LEPR* by the genotypes for four ethnicities are shown in [Table **4**](#pone-0075135-t004){ref-type="table"}. We did not find any differences in mRNA expression by genotypes among different ethnicities. No trend of transcript expression levels by genotypes was found for *LEP* or *LEPR*. These data suggest that the variants under investigation may not have a significant effect on gene expression, at least at mRNA levels.

10.1371/journal.pone.0075135.t004

###### *LEP* and *LEPR* mRNA expression by the genotypes of SNPs, using data from the HapMap ^**a**^.

  Populations   *LEP* rs7799039 (G2548A)   *LEPR* rs1137101 (Q223R)                                                                
  ------------- -------------------------- -------------------------- ----------- ------- ------- ------- ---- ----------- ------- -------
  CHB           GG                         4                          8.82±0.22           0.913   GG      36   8.70±0.23           0.819
                AG                         15                         8.66±0.23   0.229           AG      8    8.78±0.22   0.402   
                AA                         26                         8.73±0.23   0.422           AA      1    8.53        0.468   
                AG/AA                      41                         8.70±0.23   0.311           AG/AA   9    8.75±0.22   0.575   
  JPT ^d^       GG                         1                          8.41                0.653   GG      32   8.52±0.22           0.774
                AG                         18                         8.51±0.24   0.688           AG      12   8.50±0.15   0.774   
                AA                         26                         8.53±0.20   0.562           AA      0    \-          \-      
                AG/AA                      44                         8.52±0.21   0.609           AG/AA   12   8.50±0.15   0.774   
  CEU ^d^       GG                         20                         8.53±0.30           0.473   GG      26   8.49±0.27           0.427
                AG                         44                         8.45±0.24   0.228           AG      44   8.48±0.23   0.902   
                AA                         21                         8.47±0.25   0.492           AA      19   8.43±0.22   0.421   
                AG/AA                      65                         8.45±0.24   0.242           AG/AA   63   8.46±0.23   0.674   
  YRI ^d^       GG                         87                         8.57±0.24           0.749   GG      31   8.57±0.27           0.698
                AG                         2                          8.62±0.05   0.749           AG      46   8.59±0.22   0.728   
                AA                         0                          \-          \-              AA      12   8.51±0.26   0.561   
                AG/AA                      2                          8.62±0.05   0.749           AG/AA   58   8.57±0.22   0.936   

^a^ Genotyping data and mRNA expression levels for *LEP* or *LEPR* by genotypes were obtained from the HapMap phase II release 23 data from EBV-transformed lymphoblastoid cell lines from 270 individuals, including 45 unrelated Han Chinese in Beijing (CHB).

^b^ Two-side Student's *t* test within the stratum.

^c^ *P* values for the trend test of mRNA expression among three genotypes for each SNP from a general linear model.

^d^ There were missing data because genotyping data for six individuals were not available for *LEP* and three individuals were not available for *LEPR.*

Publication bias {#s3.4}
----------------

For *LEP* G2548A (or A19G), there was evidence for publication bias under a homozygous additive model (the Egger's test: AA vs. GG: *P*=0.034); however, this was not observed under other genetic models (AG vs. GG: *P*=0.174; recessive model: *P*=0.138; dominant model: *P*=0.071). The publication bias may be ascribed to small sample sizes the included studies had. When studies with cases smaller than 150 in numbers were excluded, the publication bias disappeared, but the significant association also disappeared.

No publication bias was detected for *LEPR* Q223R (the Egger's test: GG vs. AA: *P*=0.559, AG vs. AA: *P*=0.686, recessive model: *P*=0.600, dominant model: *P*=0.600).

Discussion {#s4}
==========

It is well recognized that individual susceptibility to cancer varies, even with the same environmental exposure. Therefore, a role for genetic variation, such as SNPs of genes involved in carcinogenesis, has been suggested. Epidemiological studies have shown that overweight and obesity might be associated with an increased risk of cardiovascular disease and type II diabetes; moreover, excessive body weight has been directly associated with risk of cancer at several organ sites, including the colon, breasts (in postmenopausal women), endometrium, esophagus, and kidney \[[@B51]\]. Formerly, immune dysfunction has been shown to be associated with obesity \[[@B20]\], whereas leptin concentrations were recently found to be higher in Africans, compared with Caucasians, after adjustment for BMI and other factors \[[@B52]\].

The Q223R SNP (but not the K109R or K656N SNPs) of the *LEPR* gene has been reported to be associated with obesity and to predict a small percentage of body weight and body composition variability in a genetically homogeneous population \[[@B8]\]. Previous reports demonstrated that genetic variation in *LEPR* affected cancer susceptibility with significantly higher frequency of the *LEPR* 223Arg allele in patients than in controls \[[@B9],[@B11],[@B22],[@B24],[@B33]\]; however, this association was not be replicated by later studies \[[@B14],[@B16],[@B19],[@B23],[@B31],[@B36]\]. Likewise, previous reports also demonstrated that *LEP* 2548AA was associated with an increased risk of cancer \[[@B12],[@B13],[@B20],[@B21],[@B33],[@B34]\]; however, replication of this finding by others also failed as well \[[@B25],[@B28],[@B31]\].

In this meta-analysis, we found statistical evidence for a significant but week association of cancer risk with the *LEP* G2548A (or A19G) SNP but not with the *LEPR* Q223R SNP. There are several biologically plausible explanations for this finding. Firstly, it has been described that genetic variants in the promoter region of *LEP* can influence leptin expression, possibly at the transcriptional level, thereby altering adipose secretion levels of the hormone \[[@B17]\]. Additionally, it is also likely that the observed association may be due to improved study power from pooling studies with small sample sizes that separately may have had insufficient statistical power to detect a weak effect. Thus, in the genotype-based mRNA expression analysis using data from HapMap for the *LEP* G2548A, we did not find statistical difference may be ascribed to small sample size for each ethnicity or the G2548A may have a weak effect. In the subgroup analysis by tumor type, an observed association between *LEP* 2548A (or 19G) and risk of prostate cancer suggests that this SNP may be disease specific, because all the prostate cancer patients were Caucasian decent. In the subgroup analysis by sample size, we found that the association between studies with small sample sizes and cancer risk for the G2548A polymorphism may be ascribed to some selection bias. In contrast to another meta-analysis, however, we were not able to find a statistically significant association between *LEPR* Q223R and risk of breast cancer \[[@B53]\]. This could be explained by the fact that we included a latest study on breast cancer that included 1972 cases and 1775 controls, a null study that was not included in the previous meta-analysis.

In exploring possible functional relevance of the SNPs under investigation, we did not find any differences in or trends of the mRNA expression levels of *LEP* and *LEPR* by their genotypes in four ethnic groups. Cancer is a complex and multifactorial disease, and gene-gene and gene-environment interactions may contribute greatly to its occurrence, but a single nucleotide alteration may be insufficient to alter the mRNA expression, even for those SNPs in the coding regions that may lead to amino acid change or the polymorphisms in a promoter may have a subtle, potential effect on the gene expression.

Though we performed this meta-analysis using the pooled data that can yield more reliable or statistically more powerful results, several limitations should be addressed. First, significant heterogeneity were found for both of these two polymorphisms that may influence the interpretation of the results. Second, the individual sample sizes for cases of most studies included in the analysis were relatively small (\<500) except for seven studies \[[@B25],[@B27]-[@B29],[@B34],[@B36],[@B39]\], and there were only one study based on the population of Latin Americans, Africans and Asians for the G2548A polymorphism, respectively, which did not provide insufficient statistical power to investigate the real association. Third, most of the studies used hospital-based controls that may result in some selection biases. Finally, the lacking of original data such as age, sex, smoking and drinking status, BMI, environmental factors and other lifestyle, limited our ability to further evaluate of gene-gene and gene-environment interactions.

In conclusion, this meta-analysis found that the *LEP* 2548AA genotype was associated with a weakly increased risk of cancer, mainly for prostate cancer, while *LEPR* Q223R was not. However, given the relatively limited sample sizes and the lack of detailed information, this analysis with mixed ethnicities was not able to address cancer outcomes and biological evidence for genotype-phenotype (mRNA expression) correlations. It is clear that further studies are warranted to validate the association between the *LEP* G2548A polymorphism and cancer risk.
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